Marco Herold

Marco Herold, CEO of the Olivia Newton-John Cancer Research Institute, delves into the groundbreaking world of CRISPR gene editing. He discusses the first-ever personalized gene therapy treatment for a baby, highlighting its transformative potential. The conversation covers innovative CRISPR applications in cancer treatment, including new methods enhancing immune responses against glioblastoma. Herold also shares insights on the rapid development timeline of these therapies and their future implications in medicine, emphasizing both the excitement and challenges ahead.